Table 1 Inclusion and exclusion criteria

Patients with histologically confirmed glioblastoma without having been previously treated with chemotherapy or radiotherapy

Participation in another clinical trial. If the patient has previously participated in another clinical trial, he should wait some time determined by the investigator

Ability to provide informed consent and express their desire to fulfill all protocol requirements during the study period

Patients diagnosed with other malignancies except basal cell carcinoma or scaly skin, cervical carcinoma in situ adequately treated or other tumors treated curatively without recurrence for 3 or more years

Age between 18 and 70 years

Pregnant or lactating women

In case of women of childbearing age, negative pregnancy test

Patients who require immunosuppressive medication

The patient should, in the investigator’s opinion, be able to comply with all clinical trial requirements

Positive serology for HIV, hepatitis B (HBsAg) or hepatitis C

Complete tumor resection surgery guided by fluorescence microscope and 5-ALA, verified by postoperative MRI. It is defined as residual injury captante contrast zero or less than 1 cm³

Inability to produce enough material for a minimum of 6 cell vaccines

Availability of sufficient tumor tissue processed under controlled conditions to develop cellular vaccines

Absolute contraindication for the remaining standard treatments glioblastoma (surgery, radiotherapy and chemotherapy)